Emend Capsules (Aprepitant) 125 mg & 80 mg

Advanced Antiemetic Protection with Emend

Emend (Aprepitant) is a potent neurokinin-1 (NK1) receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting (CINV). By blocking the NK1 receptors in the central nervous system, Emend provides essential support during cancer treatment, addressing both the acute and delayed phases of nausea.

Why Choose Emend?

Emend is a specialized treatment regimen tailored for patients undergoing chemotherapy. Its unique mechanism of action enhances the efficacy of standard antiemetic therapies, ensuring a more comfortable and manageable treatment experience.

Key Therapeutic Benefits

• Comprehensive Coverage: Effective for both acute and delayed nausea and vomiting.
• Proven Efficacy: A trusted component of CINV prevention protocols.
• Regimen Pack: Conveniently packaged with one 125 mg capsule and two 80 mg capsules to follow a standardized dosing schedule.
• Quality Innovation: Manufactured by MSD, a global leader in pharmaceutical healthcare.

Commitment to Pharmaceutical Excellence

Manufactured by MSD, Emend is produced under strict global safety and quality standards to ensure therapeutic consistency and patient safety.

Emend is a prescription-only medication. Treatment must be supervised by a qualified oncologist or healthcare professional. Please follow your physician’s instructions precisely regarding the dosing schedule and potential drug interactions. Keep this medication in a safe place, strictly out of the reach of children.